交界区反流对大隐静脉功能不全患者静脉临床严重程度评分的影响(JURY研究)
这项在10个中心开展的横断面研究纳入352例大隐静脉反流伴或不伴隐股交界区反流的C2或C3级慢性静脉功能不全患者,比较两组基线静脉临床严重程度评分(VCSS)。结果显示两组VCSS评分等效(6.4 vs 6.6,P=0.40),隐股交界区反流不是VCSS评分的显著预测因素。作者认为仅凭隐股交界区反流缺失不应决定有症状患者的治疗策略。
要点
- 大隐静脉反流患者中,伴与不伴隐股交界区反流者的VCSS评分等效(6.4 vs 6.6,P=0.40)。
- 隐股交界区反流不是VCSS评分的显著预测因素。
- 作者认为仅凭隐股交界区反流缺失不应决定有症状慢性静脉功能不全患者的治疗策略。
核心结论
- 大隐静脉反流伴或不伴隐股交界区反流患者的症状严重程度等效。
- 仅凭隐股交界区反流缺失不应决定有症状慢性静脉功能不全患者的治疗策略。
- 符合治疗临床标准的大隐静脉反流患者,无论是否伴隐股交界区反流,均应接受等效治疗。
研究设计与样本
- 横断面研究,在10个中心开展。
- 纳入标准:由治疗医师确定适合腔内消融者;年龄18至80岁;超声示大隐静脉反流伴或不伴隐股交界区反流;CEAP分级C2或C3级病变。
- 排除标准:既往深静脉血栓形成;索引肢体既往静脉消融;髂腔静脉梗阻;需既往住院的肾、肝或心力衰竭。
- 预先计算样本量,共纳入352例患者。
- 采用多重线性回归(校正患者特征)比较两组基线VCSS评分差异,并以预先设定的+1和-1等效界值检验等效性。
主要发现
- 352例患者中,64.2%(n=226)伴隐股交界区反流,35.8%(n=126)不伴。
- 两组主要临床特征无差异;队列平均年龄53.9±14.3岁,女性占74.2%,白人患者占85.8%,体重指数27.8±6.1 kg/m2。
- 伴与不伴隐股交界区反流患者的VCSS评分等效,隐股交界区反流不是VCSS评分的显著预测因素,平均VCSS评分无显著差异(6.4 vs 6.6,P=0.40)。
- 亚组分析中,C2级患者伴与不伴隐股交界区反流的VCSS评分等效;C3级患者中伴隐股交界区反流者的VCSS评分低于不伴者。
临床怎么用
- 作者认为仅凭隐股交界区反流缺失不应决定有症状慢性静脉功能不全患者的治疗策略。
- 作者认为符合治疗临床标准的大隐静脉反流患者,无论是否伴隐股交界区反流,均应接受等效治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Effective treatment options are available for chronic venous insufficiency associated with superficial venous reflux. Although many patients with C2 and C3 disease based on the CEAP (Clinical-Etiological-Anatomical-Pathophysiological) classification have combined great saphenous vein (GSV) and saphenofemoral junction (SFJ) reflux, some may not have concomitant SFJ reflux. Several payors have determined that symptom severity in patients without SFJ reflux does not warrant treatment. In patients planned for venous ablation, we tested whether Venous Clinical Severity Scores (VCSS) are equivalent in those with GSV reflux alone compared with those with both GSV and SFJ reflux. METHODS: This cross-sectional study was conducted at 10 centers. Inclusion criteria were: candidate for endovenous ablation as determined by treating physician; 18 to 80 years of age; GSV reflux with or without SFJ reflux on ultrasound; and C2 or C3 disease. Exclusion criteria were prior deep vein thrombosis; prior vein ablation on the index limb; ilio-caval obstruction; and renal, hepatic, or heart failure requiring prior hospitalization. An a priori sample size was calculated. We used multiple linear regression (adjusted for patient characteristics) to compare differences in VCSS scores of the two groups at baseline, and to test whether scores were equivalent using a priori equivalence boundaries of +1 and -1. In secondary analyses, we tested differences in VCSS scores in patients with C2 and C3 disease separately. RESULTS: A total of 352 patients were enrolled; 64.2% (n = 226) had SFJ reflux, and 35.8% (n = 126) did not. The two groups did not differ by major clinical characteristics. The mean age of the cohort was 53.9 ± 14.3 years; women comprised 74.2%; White patients 85.8%; and body mass index was 27.8 ± 6.1 kg/m2. The VCSS scores in patients with and without SFJ reflux were found to be equivalent; SFJ reflux was not a significant predictor of VCSS score; and mean VCSS scores did not differ significantly (6.4 vs 6.6, respectively, P = .40). In secondary subset analyses, VCSS scores were equivalent between C2 patients with and without SFJ reflux, and VCSS scores of C3 patients with SFJ reflux were lower than those without SFJ reflux. CONCLUSIONS: Symptom severity is equivalent in patients with GSV reflux with or without SFJ reflux. The absence of SFJ reflux alone should not determine the treatment paradigm in patients with symptomatic chronic venous insufficiency. Patients with GSV reflux who meet clinical criteria for treatment should have equivalent treatment regardless of whether or not they have SFJ reflux.
引用
- Vemuri C, Gibson KD, Pappas PJ, et al. Effect of junctional reflux on the venous clinical severity score in patients with insufficiency of the great saphenous vein (JURY study). J Vasc Surg Venous Lymphat Disord. 2023. PMID: 37956904. doi:10.1016/j.jvsv.2023.101700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。